Crescent Biopharma and Kelun-Biotech Launch Strategic Oncology Partnership
Crescent Biopharma Inc. and Kelun-Biotech have formed a strategic partnership to develop and commercialize novel oncology therapeutics. Crescent granted Kelun-Biotech exclusive rights to CR-001 in Greater China, while Crescent received exclusive rights to SKB105 outside Greater China. Both drug candidates are expected to enter Phase 1/2 clinical trials in early 2026. The collaboration aims to accelerate development and maximize the potential of these cancer treatments globally.
Crescent Biopharma Inc. has announced a strategic partnership with Kelun-Biotech to jointly develop and commercialize novel oncology therapeutics. Under the terms of the collaboration, Crescent has granted Kelun-Biotech exclusive rights to research, develop, manufacture, and commercialize CR-001, a PD-1 x VEGF bispecific antibody, in Greater China, while Crescent has received exclusive rights to develop and commercialize SKB105, an integrin beta-6-directed antibody-drug conjugate (ADC), in the United States, Europe, and other markets outside Greater China. The partnership aims to advance both drug candidates as monotherapies and in combination, with both expected to enter Phase 1⁄2 clinical trials in early 2026. The collaboration is designed to accelerate development and maximize the potential of these therapies for cancer treatment globally. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Crescent Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9596692-en) on December 04, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
